SCHEMBL1024056

SCHEMBL1024056

Cc1cccc(Cc2nsc(NC(C)CNS(=O)(=O)c3cccs3)n2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.43
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
ALDH1A1 P00352 5/20 0.40
POLB P06746 1/20 0.40
TSHR P16473 3/20 0.38
HTT P42858 2/20 0.38
TP53 P04637 2/20 0.37
CYP2C9 P11712 2/20 0.37
CYP2C19 P33261 2/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
KDM4E B2RXH2 3/20 0.37
CYP2D6 P10635 1/20 0.37
ADORA2A P29274 1/20 0.36
GLA P06280 1/20 0.36
HSD17B10 Q99714 1/20 0.36
PARP1 P09874 1/20 0.36
NPC1 O15118 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1019643 0.90 ALDH1A1 (0.36) HPGDKMT2AMEN1ALDH1A1TP53
SCHEMBL1020255 0.90 HTT (0.42) HPGDKMT2AMEN1ALDH1A1TSHR
SCHEMBL1021327 0.89 CYP2C9 (0.40) HPGDKMT2AMEN1ALDH1A1TP53
SCHEMBL1021080 0.88 PKM (0.47) KMT2AMEN1ALDH1A1POLBHTT
SCHEMBL1021126 0.86 LMNA (0.42) HPGDKMT2AMEN1ALDH1A1TP53
SCHEMBL1020710 0.85 MAPT (0.41) HPGDKMT2AMEN1TP53CYP2C9
SCHEMBL1020254 0.85 CYP2C9 (0.40) HPGDKMT2AMEN1POLBTP53
SCHEMBL1020921 0.84 CYP2C9 (0.47) HPGDKMT2AMEN1ALDH1A1POLB
SCHEMBL1020150 0.83 MEN1 (0.45) HPGDKMT2AMEN1ALDH1A1POLB
SCHEMBL1021482 0.83 TP53 (0.39) HPGDKMT2AMEN1HTTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960556-B2 Thiadiazole derivatives for the treatment of neuro-degenerative diseases NV REMYND (BE) 2011-06-14 US claimed
EP-2094677-B1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES REMYND NV (BE) 2011-01-12 EP claimed
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV REMYND (BE) 2010-06-10 US claimed
US-7960556-B2 Thiadiazole derivatives for the treatment of neuro-degenerative diseases NV REMYND (BE) 2011-06-14 US disclosed
EP-2094677-B1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES REMYND NV (BE) 2011-01-12 EP disclosed
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV REMYND (BE) 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES SNCA, PARK7, PRNP HPGD 271/4885KMT2A 3893/4885MEN1 4386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.